| Literature DB >> 32612930 |
Georgios Daletos1, Gregory Stephanopoulos1.
Abstract
Isoprenoids comprise one of the most chemically diverse family of natural products with high commercial interest. The structural diversity of isoprenoids is mainly due to the modular activity of three distinct classes of enzymes, including prenyl diphosphate synthases, terpene synthases, and cytochrome P450s. The heterologous expression of these enzymes in microbial systems is suggested to be a promising sustainable way for the production of isoprenoids. Several limitations are associated with native enzymes, such as low stability, activity, and expression profiles. To address these challenges, protein engineering has been applied to improve the catalytic activity, selectivity, and substrate turnover of enzymes. In addition, the natural promiscuity and modular fashion of isoprenoid enzymes render them excellent targets for combinatorial studies and the production of new-to-nature metabolites. In this review, we discuss key individual and multienzyme level strategies for the successful implementation of enzyme engineering towards efficient microbial production of high-value isoprenoids. Challenges and future directions of protein engineering as a complementary strategy to metabolic engineering are likewise outlined.Entities:
Keywords: Activity; Enzyme engineering; Isoprenoids; Microbial hosts; Promiscuity; Selectivity
Year: 2020 PMID: 32612930 PMCID: PMC7322351 DOI: 10.1016/j.mec.2020.e00129
Source DB: PubMed Journal: Metab Eng Commun ISSN: 2214-0301
Fig. 1Schematic representation of isoprenoid biosynthesis. Key biosynthetic steps in the mevalonate (MVA) and 2-C-methyl-d-erythritol-4-phosphate (MEP) pathways, along with selected examples of monoterpenes, sesquiterpenes, and diterpenes, are illustrated. Double arrows indicate multiple enzymatic steps. Abbreviations: AACT, acetoacetyl-coenzyme A thiolase; Pyr, pyruvate; G3P, glyceraldehyde 3-phosphate; DXS, 1-deoxy-d-xylulose-5-phosphate synthase; DXR, 1-deoxy-d-xylulose-5-phosphate reductoisomerase; HMGS, 3-hydroxy-3-methylglutaryl coenzyme A synthase; HMGR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; IDI, isopentenyl diphosphate isomerase; GPP, geranyl diphosphate; FPP, farnesyl diphosphate; GGPP, geranylgeranyl diphosphate; LS, limonene synthase; ADS, amorpha-4,11-diene synthase; TXS, taxa-4(5),11(12)-diene synthase; CYP71AV1, amorpha-4,11-diene 12-hydroxylase; CYP725A4, taxa-4(5),11(12)-diene 5α-hydroxylase.
Fig. 2Schematic illustration of protein engineering strategies. Directed evolution and rational engineering are complementary approaches and their combination is commonly the preferred option for optimal construction of the desired enzyme variants.
Fig. 3Engineering approaches of individual enzymes for increased production of isoprenoids. (A) Enhancement of catalytic activity, (B) Altering catalytic specificity, and (C) Deregulation of feedback inhibition. For simplicity reasons, the hypothetical enzyme follows Michaelis-Menten kinetics. Enzyme structural models were constructed using the SWISS-MODEL server (Bienert et al., 2016).
Fig. 4Engineering approaches of pathway enzymes for enhanced production of isoprenoids. (A) Fusion of enzymes, (B) Protein scaffolding, and (C) Construction of de novo pathways through combinatorial biosynthesis and protein engineering for the production of non-natural isoprenoids. Examples of natural and non-natural isoprenoids were extracted from (Guo et al., 2013; Ignea et al., 2015a; Ro et al., 2005). Enzyme structural models were constructed using the SWISS-MODEL server (Bienert et al., 2016).
Summary of studies employing the protein fusion approach for enhanced in vivo production of isoprenoids.
| Strategy | Host organism | Target compound | Scale/Medium | Titer/Content | Fold-increase | Reference |
|---|---|---|---|---|---|---|
| Fusion variants of | Patchoulol | 1.1-liter bioreactor/Galactose-based mineral medium | 40.9 mg/L | 1.2 | ||
| Fusion of | ( | Test tube/Yeast malt broth | ~1.1 mg/L | 2.9 | ||
| Fusion of | Miltiradiene | Flask/YPD broth | 3.1 mg/L | 4.4 | ||
| Fusion of | Bisabolene | Flask/Galactose-based minimal broth | ~150 mg/L | ~2 | ||
| Fusion of | Flask/Rich (2xYT) medium | 86.8 mg/L | 1.5 | |||
| Construction of a tridomain fusion protein (CrtB, CrtI, CrtY) harboring the | Flask/YPG broth | ~2.7 mg/g DCW | 2.2 | |||
| Fusion of | Amorpha-4-11-diene | 2-liter bioreactor/Galactose-based mineral medium | 25.1 mg/L | ~2 | ||
| Sclareol | Flask/Galactose -raffinose-based selective medium | |||||
| Fusion protein of Bts1p and Erg20p(F96C) | 13 | Flask/YPD broth | 23.3 mg/L | 3 | ||
| Fusion between | Flask/Modified 2xYT | 115.6 mg/L | 15 | |||
| Fusion of | Astaxanthin | Flask/Luria-Bertani medium | 610 μg/g DCW | 1.4 |
Abbreviations: BTS1, gene encoding for geranylgeranyl diphosphate synthase (Bts1p); DPP1, gene encoding for diacylglycerol diphosphate phosphatase 1; ERG9, gene encoding for squalene synthase; ERG20, gene encoding for farnesyl diphosphate synthetase (Erg20p); ispA, gene encoding for farnesyl diphosphate synthase; SmKSL, kaurene synthase-like from Salvia miltiorrhiza; SmCPS, copalyl diphosphate synthase from Salvia miltiorrhiza; CrtB, phytoene synthase; CrtI, phytoene desaturase; CrtY, lycopene cyclase; CcCLS, Cistus creticus 8-hydroxy copalyl diphosphate synthase; CrtW, β-carotene ketolase; CrtZ, β-carotene hydroxylase; DCW, dry cell weight; Yeast extract-Peptone-Dextrose (YPD); Yeast extract-Peptone-Glycerol (YPG); YT, Yeast extract-Tryptone.